Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains
- PMID: 21494911
- DOI: 10.1007/s10096-011-1220-3
Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains
Abstract
The spread of multiresistant bacteria increases the need for new antibiotics. The observation that some nucleoside analogues have antibacterial activity led us to further investigate the antimicrobial activity and resistance of zidovudine (AZT). We determined the minimum inhibition concentration (MIC), studied time-kill curves, induced resistant bacteria and sequenced the gene for thymidine kinase. We demonstrate that AZT has a bactericidal effect on some enterobacteria. However, AZT could induce resistance in Escherichia coli. These resistances were associated with various modifications in the thymidine kinase gene. In particular, we observed the presence in this gene of an insertion sequence (IS) similar to IS911 of Shigella dysenteriae in two resistant clones. No cross-resistance with classical antibiotics in strains with modified thymidine kinase gene was observed. Finally, an additive or synergistic activity between AZT and the two aminoglycoside antibiotics amikacin and gentamicin was observed. We demonstrate the bactericidal activity of AZT and show synergy in association with gentamicin. Genetic modifications in resistant bacteria were identified. Our results indicate that AZT could potentially be added in the treatment of infections with enterobacteria or represent the basis for the development of derivatives with better activity and inducing less resistance.
Similar articles
-
Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli.Int J Antimicrob Agents. 2018 Dec;52(6):783-789. doi: 10.1016/j.ijantimicag.2018.08.010. Epub 2018 Aug 21. Int J Antimicrob Agents. 2018. PMID: 30138665 Clinical Trial.
-
Urinary bactericidal activity of colistin and azidothymidine combinations against mcr-1-positive colistin-resistant Escherichia coli.Int J Antimicrob Agents. 2019 Jul;54(1):55-61. doi: 10.1016/j.ijantimicag.2019.04.011. Epub 2019 Apr 26. Int J Antimicrob Agents. 2019. PMID: 31034939 Clinical Trial.
-
Synergistic effects of antimicrobial peptide DP7 combined with antibiotics against multidrug-resistant bacteria.Drug Des Devel Ther. 2017 Mar 22;11:939-946. doi: 10.2147/DDDT.S107195. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28356719 Free PMC article.
-
Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.Am J Med. 1986 Jun 30;80(6B):126-37. doi: 10.1016/0002-9343(86)90490-0. Am J Med. 1986. PMID: 3088998 Review.
-
Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.Am J Med. 1990 May 21;88(5B):8S-10S. doi: 10.1016/0002-9343(90)90414-9. Am J Med. 1990. PMID: 2186629 Review.
Cited by
-
Drug Repurposing Approaches towards Defeating Multidrug-Resistant Gram-Negative Pathogens: Novel Polymyxin/Non-Antibiotic Combinations.Pathogens. 2022 Nov 25;11(12):1420. doi: 10.3390/pathogens11121420. Pathogens. 2022. PMID: 36558754 Free PMC article. Review.
-
Design and Synthesis of Novel Antimicrobial Agents.Antibiotics (Basel). 2023 Mar 22;12(3):628. doi: 10.3390/antibiotics12030628. Antibiotics (Basel). 2023. PMID: 36978495 Free PMC article. Review.
-
Pegylation approach applied to erlotinib-carbonic anhydrase inhibitors hybrids towards anticancer agents.RSC Med Chem. 2025 Apr 28. doi: 10.1039/d5md00109a. Online ahead of print. RSC Med Chem. 2025. PMID: 40656836 Free PMC article.
-
Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria.Front Cell Infect Microbiol. 2019 Jun 11;9:193. doi: 10.3389/fcimb.2019.00193. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 31245302 Free PMC article. Review.
-
Zidovudine in synergistic combination with nitrofurantoin or omadacycline: in vitro and in murine urinary tract or lung infection evaluation against multidrug-resistant Klebsiella pneumoniae.Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0034424. doi: 10.1128/aac.00344-24. Epub 2024 Aug 28. Antimicrob Agents Chemother. 2024. PMID: 39194261 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases